Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-06-09FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) submitted by AbbVie. The action involves Depakote Sprinkl…
-
FDA approval · 2014-06-09FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie.
-
FDA approval · 2014-06-09FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2014-06-06FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) by Novartis Pharmaceuticals Corporation, representing a regulatory upd…
-
FDA approval · 2014-06-04FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA Supplemental Application approval for VIMPAT (lacosamide) by UCB, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-06-02FDA Approved: DIVALPROEX SODIUM — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original ANDA for divalproex sodium, enabling a generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2014-05-23Clinical Trial Update: Study on Migraine and Headache in Epileptic Patients
The clinical trial evaluating migraine and headache in epileptic patients has completed. No specific drug names are provided in the excerpt.
-
CLINICAL_TRIALS trial_result · 2014-05-22Clinical Trial Update: Development and Clinical Application of [11C]Verapamil-PET [Phase 2]
Phase 2 trial update on using [11C]Verapamil-PET imaging for epilepsy.
-
CLINICAL_TRIALS trial_result · 2014-05-13Clinical Trial Update: Combined Role of Position Emission Tomography (PET) and Magnetoencephalography (MEG) in Nonlesional Epilepsy [Phase 3]
Phase 3 clinical trial evaluating the combined use of PET and MEG for nonlesional epilepsy has completed.
-
FDA approval · 2014-05-08FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2014-05-08FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Trileptal (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation, resulting in ch…
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures [Phase 3]
Phase 3 study evaluating USL255 for refractory partial-onset seizures has completed. Results were posted in 2014.
-
FDA approval · 2014-04-24FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Supplemental Application (Par Health USA, LLC)
FDA approves a supplemental abbreviated new drug application for Lamotrigine Extended Release from Par Health USA, LLC.
-
CLINICAL_TRIALS trial_result · 2014-04-23Clinical Trial Update: Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures [Phase 3]
Phase 3 trial results evaluate converting to lacosamide monotherapy for partial-onset seizures, reporting on efficacy and safety.
-
FDA approval · 2014-04-18FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TROKENDI XR (topiramate extended-release) from Supernus Pharmaceuticals, Inc. The action may…
-
FDA approval · 2014-04-17FDA Approved: PHENYTOIN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved an original application for PHENYTOIN (generic phenytoin) by Sun Pharmaceutical Industries.
-
CLINICAL_TRIALS research · 2014-04-10Clinical Trial Update: Tonicity Monitor For Epilepsy and Hypertonic Disorders [NA]
Clinical trial update about a tonicity monitor for epilepsy; current status is unknown.
-
CLINICAL_TRIALS research · 2014-04-04Clinical Trial Update: Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex [NA]
A long-term prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy related to tube…
-
FDA approval · 2014-04-03FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) from Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2014-04-03Clinical Trial Update: Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours [Phase 2]
Phase 2 double-blind study in pediatric epilepsy comparing subject flavor preference for an eslicarbazepine acetate suspension formulation (…
-
CLINICAL_TRIALS research · 2014-03-28Clinical Trial Update: Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment
This clinical trial update examines retention rates for three antiepileptic drugs—topiramate, levetiracetam, and oxcarbazepine—in long-term …
-
CLINICAL_TRIALS trial_result · 2014-03-27Clinical Trial Update: Biomarkers In Seizure To Predict Recurrence and Severe Outcomes
Completed clinical trial evaluating biomarkers S-100b and copeptin to predict seizure recurrence and severe outcomes.
-
CLINICAL_TRIALS trial_result · 2014-03-26Clinical Trial Update: Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures [Phase 3]
Phase 3 study evaluating adjunctive topiramate in infants aged 1–24 months for partial-onset seizures has completed.
-
FDA approval · 2014-03-20FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Sun Pharmaceutical Industries.
-
FDA approval · 2014-03-18FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for DIVALPROEX SODIUM submitted by Bionpharma Inc.